These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29485062)

  • 1. The Impact of Academic Facility Type and Case Volume on Survival in Patients Undergoing Curative Radiation Therapy for Muscle-Invasive Bladder Cancer.
    Bajaj A; Martin B; Bhasin R; Hentz C; Block AM; Harkenrider MM; Solanki AA
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):851-857. PubMed ID: 29485062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Radiotherapy Facility Volume on the Survival and Guideline Concordance of Patients With Muscle-invasive Bladder Cancer Receiving Bladder-preservation Therapy.
    D'Rummo KA; TenNapel MJ; Shen X
    Am J Clin Oncol; 2019 Sep; 42(9):705-710. PubMed ID: 31368905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
    Korpics MC; Block AM; Martin B; Hentz C; Gaynor ER; Henry E; Harkenrider MM; Solanki AA
    Cancer; 2017 Sep; 123(18):3524-3531. PubMed ID: 28581675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of treating facilities' type and volume in patients with major salivary gland cancer.
    Bollig CA; Zitsch RP
    Laryngoscope; 2019 Oct; 129(10):2321-2327. PubMed ID: 30698823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.
    David JM; Ho AS; Luu M; Yoshida EJ; Kim S; Mita AC; Scher KS; Shiao SL; Tighiouart M; Zumsteg ZS
    Cancer; 2017 Oct; 123(20):3933-3942. PubMed ID: 28640546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facility Volume and Survival in Nasopharyngeal Carcinoma.
    Yoshida EJ; Luu M; David JM; Kim S; Mita A; Scher K; Shiao SL; Tighiouart M; Lee NY; Ho AS; Zumsteg ZS
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):408-417. PubMed ID: 29100787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.
    Chen YW; Mahal BA; Muralidhar V; Nezolosky M; Beard CJ; Den RB; Feng FY; Hoffman KE; Martin NE; Orio PF; Nguyen PL
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):683-90. PubMed ID: 26972640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma.
    Lee GC; Gamblin TC; Fong ZV; Ferrone CR; Goyal L; Lillemoe KD; Blaszkowsky LS; Tanabe KK; Qadan M
    Ann Surg Oncol; 2019 Nov; 26(12):4091-4099. PubMed ID: 31368018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.
    Gray PJ; Fedewa SA; Shipley WU; Efstathiou JA; Lin CC; Zietman AL; Virgo KS
    Eur Urol; 2013 May; 63(5):823-9. PubMed ID: 23200811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Treatment at a High-volume Center Associated with an Improved Survival for Primary Malignant Bone Tumors?
    Malik AT; Alexander JH; Khan SN; Scharschmidt TJ
    Clin Orthop Relat Res; 2020 Mar; 478(3):631-642. PubMed ID: 31714413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer.
    Ryan S; Serrell EC; Karabon P; Mills G; Hansen M; Hayn M; Menon M; Trinh QD; Abdollah F; Sammon JD
    J Urol; 2018 Feb; 199(2):424-429. PubMed ID: 29030318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Travel distance and overall survival in hepatocellular cancer care.
    Siegel JB; Allen S; Engelhardt KE; Morgan KA; Lancaster WP
    Am J Surg; 2021 Sep; 222(3):584-593. PubMed ID: 33413878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between facility volume and mortality of patients with classic Hodgkin lymphoma.
    Goyal G; Tella SH; Funni S; Kommalapati A; Inselman JW; Shah ND; Go RS; Ansell SM
    Cancer; 2020 Feb; 126(4):757-764. PubMed ID: 31714588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved surgical outcomes following radical cystectomy at high-volume centers influence overall survival.
    Scarberry K; Berger NG; Scarberry KB; Agrawal S; Francis JJ; Yih JM; Gonzalez CM; Abouassaly R
    Urol Oncol; 2018 Jun; 36(6):308.e11-308.e17. PubMed ID: 29628316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations Between Travel Distance, Hospital Volume, and Outcomes Following Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer.
    Xia L; Taylor BL; Mamtani R; Christodouleas JP; Guzzo TJ
    Urology; 2018 Apr; 114():87-94. PubMed ID: 29305205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers.
    Kool R; Marcq G; Breau RH; Black PC; Shayegan B; Kim M; Busca I; Abdi H; Dawidek MT; Uy M; Fervaha G; Cury FL; Alimohamed NS; Izawa JI; Jeldres C; Rendon R; Siemens DR; Kulkarni GS; Kassouf W
    Eur Urol Oncol; 2023 Dec; 6(6):597-603. PubMed ID: 37005214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early mortality and overall survival of acute myeloid leukemia based on facility type.
    Bhatt VR; Shostrom V; Giri S; Gundabolu K; Monirul Islam KM; Appelbaum FR; Maness LJ
    Am J Hematol; 2017 Aug; 92(8):764-771. PubMed ID: 28437868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimodality therapy for esophageal cancer at high volume facilities is associated with improved postoperative outcomes and overall survival.
    Haque W; Verma V; Butler EB; Teh BS
    Dis Esophagus; 2019 Apr; 32(4):. PubMed ID: 30052835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Treatment at High-Volume Facilities and Improved Overall Survival in Soft Tissue Sarcomas.
    Venigalla S; Nead KT; Sebro R; Guttmann DM; Sharma S; Simone CB; Levin WP; Wilson RJ; Weber KL; Shabason JE
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1004-1015. PubMed ID: 29485042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.